Screening for HPV and Cervical Cancer in Young Women With Perinatally Acquired HIV

Screening for Human Papillomavirus and Cervical Cancer in Young Women With Perinatally Acquired HIV

This is a cross-sectional, observational study of high-risk HPV status, cervical cytology and HPV vaccine uptake and response in young women with perinatally acquired HIV.

This is an observational study of cervical cytology assessment, high risk human papilloma virus (hr-HPV) status, and HPV antibody titres amongst adult women living with perinatally acquired HIV infection (PaHIV). Eligible consenting participants will have two samples taken; firstly, a cervical sample tested for cytology and Hr-HPV with the Cepheid GeneXpert HPV; secondly serum will be assessed for hr-HPV serology. All women with PaHIV, vaccinated and unvaccinated for HPV, over the age of 18 years will be eligible and will be recruited into one of two cohorts: (1) sexually active women: full study, cervical and blood sampling or (2) non-sexually active women, blood sampling only (total n=80). Follow up for abnormal smear results or hr-HPV positivity will be arranged through colposcopy.

Inclusion Criteria - Cohort 1:

• Perinatally acquired HIV aged 18+
• Sexually active
• Able to give informed consent

Inclusion Criteria - Cohort 2:

• Perinatally acquired HIV aged 18+
• Able to give informed consent

Exclusion Criteria - Cohort 1:

• Pregnancy
• Not sexually active
• Previous total abdominal hysterectomy
• Unable to give informed consent

Exclusion Criteria - Cohort 2:

• Unable to give informed consent